Sage Therapeutics (NASDAQ:SAGE) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Sage Therapeutics (NASDAQ:SAGE) issued its earnings results on Tuesday. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02), Zacks reports. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%.

Sage Therapeutics Stock Performance

SAGE traded down $0.07 during mid-day trading on Tuesday, reaching $7.19. 2,063,607 shares of the stock were exchanged, compared to its average volume of 2,513,681. Sage Therapeutics has a 1 year low of $4.62 and a 1 year high of $27.39. The stock has a market capitalization of $439.81 million, a PE ratio of -1.29 and a beta of 0.94. The company has a 50 day moving average price of $6.28 and a two-hundred day moving average price of $6.96.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on SAGE shares. TD Cowen dropped their price objective on shares of Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating for the company in a report on Thursday, November 21st. Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a research report on Wednesday, November 20th. Scotiabank dropped their target price on shares of Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating on the stock in a report on Wednesday, October 30th. Royal Bank of Canada raised Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 target price for the company in a research note on Thursday, November 21st. Finally, Stifel Nicolaus cut their price target on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating on the stock in a report on Monday, December 16th. Three analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $10.53.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.